New drug combo aims to tackle deadly pancreatic cancer
NCT ID NCT07665684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with newly diagnosed metastatic pancreatic cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
samuraciclib (a CDK7 inhibitor) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If successful, this could lead to a new treatment option for a hard-to-treat type of pancreatic cancer, potentially improving how long patients live or how well they respond to therapy.
What could go wrong
This is an early-phase trial with only 67 participants, so results may not apply to all patients. The drug combination may cause severe side effects or fail to improve outcomes compared to standard chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCINOUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact